世界の心臓バイオマーカー市場

当レポートでは、世界の心臓バイオマーカー市場について調査し、市場の現状と今後の成長予測、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 業界概要

• 概要
• 主な心臓バイオマーカーと特性
• タイプ別分析
• 競合環境
• 参入企業間の激しい競争
• 主要ベンダー
• 近年の技術革新
• 厳しい法規制とその他の課題　他

第3章 成長促進因子、市場動向、課題

• 心血管疾患の経済的、社会的負担の現実
• 人口爆発、高齢化、寿命の延伸による心血管疾患の増加
• 正確、タイムリーな診断と予後の鍵となる心臓バイオマーカー
• 新規バイオマーカーの商品化
• 心臓バイオマーカー：患者トリアージの強力ツール　他

第4章 製品概要

• 心臓マーカーアッセイ検査の必要性
• 心臓マーカーと心筋梗塞
• 心筋梗塞イベント後の連鎖反応
• 心筋梗塞イベント後のアクションプラン
• 心臓マーカーの種類　他

第5章 競合環境

• 主要企業

第6章 世界市場見通し

第7章 地域別市場動向

• 米国
• カナダ
• 日本
• 欧州
• アジア太平洋地域
• ラテンアメリカ

第8章 企業プロファイル

This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Thousand by the following Testing Locations: Laboratory Testing, and Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 39 companies including many key and niche players such as -

Abbott Diagnostics, Inc.
Quidel Corporation
Beckman Coulter, Inc.
BG Medicine, Inc.
biomerieux SA
Boditech Med Inc.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definition and Scope of Study
• Cardiac Biomarkers
  • Testing Location
    • Laboratory Testing
    • Point of Care Testing
  • Types of Cardiac Biomarkers
    • Cardiac Troponin
    • Natriuretic Peptides
    • BNP (B-type Natriuretic Peptide)
    • NT-proBNP (N-terminal proBNP)
    • Others
    • Creatine Kinase-MB (CK-MB)
    • Myoglobin

2. INDUSTRY OVERVIEW

• A Curtain Raiser
• Major Cardiac Markers and their Properties
• Market Set to Record Strong Growth Led by Advancements in Cardiac Biomarker Combinations
• North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
• Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction
  • Table 1: Rising Importance of Cardiac Biomarkers in the overall POCT Market (2017): Percentage Share of Cardiac Biomarkers, Cholesterol, Coagulation, Infectious Diseases, Pregnancy, Self-monitoring Blood Glucose and Others (includes corresponding Graph/Chart)
• Analysis by Type of Cardiac Biomarker Assay/Test
  • Emerging Markets, New Product Introductions Hold Key to Reviving Saturated Cardiac Troponin Assays Market
• Competitive Landscape
• Intense Competition among Players in the Cardiac Diagnostics Market
• Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits
• Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands
• Other Recent Innovations
• Lipid Biomarker Panel to Detect HfrEF
• VectraplexECG System with CEB(r) Cardiac Electrical Biomarker
• Cardiac Biomarkers on Smartphone
• Stringent Regulations and Other Challenges

3. MARKET GROWTH DRIVERS, TRENDS & ISSUES

• The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease
  • Table 2: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart)
• Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs
  • Table 3: Global Population Estimates (in Millions): 2017-2100 (includes corresponding Graph/Chart)
  • Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
  • Table 5: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • Table 6: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
  • Table 7: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
• Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
• Commercialization of Novel Biomarkers to Drive Market Growth
• Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
• Cardiac Biomarkers - A Powerful Tool for Patient Triaging
• Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
• Government Support Instrumental for Boosting Market Momentum
• Secretoneurin Biomarker - a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
• High-Performance Techniques Drive Biomarker Discovery in Cardiology
• Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
• Biomarkers - A Promising Diagnostic Tool for ACS
• Biomarker Discovery for ACS to Undergo Significant Changes
• Cardiac Biomarker Play Critical Role in Stroke Diagnosis
• Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
• Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth

4. PRODUCT OVERVIEW

• Necessity of a Cardiac Marker Assay Test
• Cardiac Markers and Myocardial Infarction (MI)
• Chain Reaction after an Event of MI
• Action Plan after an Event of MI
• Protocol for Conducting AMI Markers Tests
• Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
• Cardiac Markers and Congestive Heart Failure (Chf)
• Types of Cardiac Biomarkers
• Major Cardiac Markers and their Properties
• Creatine Kinase - The Gold Standard Losing Sheen
  • Isomers
  • Kinetics
  • Purpose of Test and When to Order
  • Evaluation
  • Points to remember
• Cardiac Troponin
  • Troponin Tissue-Specific Subtypes
  • Other Diseases
  • Uses of Troponin Tests
  • New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
• Myoglobin
  • Purpose of Test and When to Order
  • Testing and Evaluation
  • Points of Caution
• Natriuretic Peptides
  • BNP (B-type Natriuretic Peptide)
  • NT-proBNP (N-terminal proBNP)
    • Purpose of Tests and When to Order
    • Testing and Evaluation
    • Points to Remember
    • Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review
    • Choosing the Right BNP and NT proBNP Assay Kit in the Market
    • Evolution of BNP and NT proBNP Market
    • NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function
• Other Important Cardiac Biomarkers
  • Homocysteine
  • C-Reactive Protein
  • Plasminogen Activator Inhibitor-1
  • D-Dimer
    • Thrombus Precursor Protein
    • Galectin-3 Biomarker
    • Galectin-3: An Overview of Clinical Studies
    • Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis
    • Potential Future Cardiac Biomarkers
• Location of Cardiac Biomarker Testing
• Laboratory Cardiac Testing
• Point-of-Care Cardiac Testing

5. COMPETITIVE LANDSCAPE

• 5.1 Focus on Select Players
• Abbott Diagnostics, Inc. (USA)
• Quidel Corporation (USA)
• Beckman Coulter, Inc. (USA)
• BG Medicine, Inc. (USA)
• biomerieux SA (France)
• Boditech Med Inc. (South Korea)
• Labsystems Diagnostics OY (Finland)
• LifeSign LLC (USA)
• LSI Medience Corporation (Japan)
• Ortho-Clinical Diagnostics, Inc. (USA)
• Randox Laboratories Ltd. (UK)
• Response Biomedical Corp. (Canada)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers (USA)
• Merck KGaA (Germany)
• 5.2 Product Introductions
• Prevencio Introduces Clinical Trial Business, and Targets to Release LDT Cardio Test by Year End
• Prothena Presents Novel Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
• Fujirebio Europe Introduces the Lumipulse(r) G hs Troponin I and Lumipulse G Myoglobin immunoassays
• 5.3 Recent Industry Activity
• Beckman Coulter Diagnostics Receives Clearance from Health Canada for Access hsTnI
• Ortho Clinical Diagnostics and Sphingotec Announces Strategic Agreement Regarding Novel Biomarker
• Abbott Acquires Alere Inc.
• Bristol-Myers Squibb and Nordic Bioscience Collaborates for Fibrosis Biomarker Technology

6. GLOBAL MARKET PERSPECTIVE

• Cardiac Biomarkers Testing By Geographic Region
  • Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 9: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 10: World 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 Cardiac Biomarkers Testing By Location of Testing (includes corresponding Graph/Chart)
  • Table 11: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 12: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 13: World 14-Year Perspective for Cardiac Biomarkers in Laboratory Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
  • Table 14: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 15: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 16: World 14-Year Perspective for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World Markets for Years 2011, 2018, and 20247 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

• 7.1 The United States
• A. Market Analysis
  • Current and Future Analysis
  • Statistics for Cardiovascular Diseases and Stroke, and Related Risk Factors and Costs in the US
  • Table 17: Prevalence of heart disease (All types) in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
  • Table 18: Prevalence of Coronary Heart Disease in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
  • Table 19: Prevalence of Hypertension in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
  • Table 20: Prevalence of Stroke in the US Adult Population by Age (2016): Age-adjusted Percentages for Age Groups - 18-44 Years, 45-64 Years, 65-74 Years, and 75 Years & Above
  • Table 21: US Total Annual Average Expenditure for Cardiovascular Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure for Heart Disease, Hypertension, Stroke and Other CVDs (includes corresponding Graph/Chart)
• B. Market Analytics
  • Cardiac Biomarkers Testing By Location of Testing
  • Table 22: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 23: The US Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 24: The US 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.2 Canada
• Market Analysis
  • Table 25: Canadian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 26: Canadian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 27: Canadian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.3 Japan
• Market Analysis
  • Table 28: Japanese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 29: Japanese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 30: Japanese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4 Europe
• A. Market Analysis
  • Current and Future Analysis
  • Growing Prevalence of Cardiovascular Disease Propels Growth of European Cardiac Biomarkers Market
  • Cardiac Markers in Primary Care Sector
• B. Market Analytics
  • Table 31: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 32: European Historic Review Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 33: European 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Testing By Location of Testing
  • Table 34: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 35: European Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 36: European 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.1 France
• Market Analysis
  • Table 37: French Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 38: French Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 39: French 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.2 Germany
• Market Analysis
  • Table 40: German Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 41: German Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 42: German 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.3 Italy
• Market Analysis
  • Table 43: Italian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 44: Italian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 45: Italian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.4 The United Kingdom
• A. Market Analysis
  • Current and Future Analysis
• B. Market Analytics
  • Table 46: The UK Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 47: The UK Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 48: The UK 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.5 Spain
• Market Analysis
  • Table 49: Spanish Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 50: Spanish Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 51: Spanish 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.6 Russia
• Market Analysis
  • Table 52: Russian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 53: Russian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 54: Russian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.4.7 Rest of Europe
• Market Analysis
  • Table 55: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 56: Rest of Europe Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 57: Rest of Europe 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.5 Asia-Pacific
• Market Analysis
  • Table 58: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 59: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 60: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Testing By Location of Testing
  • Table 61: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 62: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 63: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.5.1 China
• Market Analysis
  • Table 64: Chinese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 65: Chinese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 66: Chinese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.5.2 India
• Market Analysis
  • Table 67: Indian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 68: Indian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 69: Indian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.5.3 Rest of Asia-Pacific
• Market Analysis
  • Table 70: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 71: Rest of Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 72: Rest of Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.6 Latin America
• Market Analysis
  • Table 73: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 74: Latin American Historic Review Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 75: Latin American 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for Brazil, and Rest of Latin America Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Testing By Location of Testing
  • Table 76: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 77: Latin American Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 78: Latin American 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.6.1 Brazil
• Market Analysis
  • Table 79: Brazilian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 80: Brazilian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 81: Brazilian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.6.2 Rest of Latin-America
• Market Analysis
  • Table 82: Rest of Latin-America Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 83: Rest of Latin-America Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 84: Rest of Latin-America 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)
• 7.7 Rest of World
• Market Analysis
  • Table 85: Rest of World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
  • Table 86: Rest of World Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing and Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 87: Rest of World 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing and Point-of-Care Testing Markets for Years 2011, 2018, and 2024 (includes corresponding Graph/Chart)

8. COMPANY PROFILES